Related Experiment Video
Updated: Jun 19, 2026
09:11
Capsular Serotyping of Streptococcus pneumoniae by Latex Agglutination
Published on: September 25, 2014
STANDARDIZATION OF ANTIMENINGOCOCCIC SERUM
The Journal of Experimental Medicine
|October 30, 2009
Summary
Testing antimeningococcic serum potency using animal protection tests proved unreliable. This method showed variable results unrelated to serum quality or clinical effectiveness, making it inferior to agglutination titer for assessing potency.
Area of Science:
- Immunology
- Microbiology
- Infectious Diseases
Background:
- Antimeningococcic serum is crucial for treating bacterial meningitis.
- Assessing the potency of such sera is vital for effective clinical application.
- Previous methods for determining serum potency have limitations.
Purpose of the Study:
- To evaluate the protective reaction in laboratory animals as a measure of antimeningococcic serum potency.
- To compare this protective test with other established indicators of serum efficacy.
Main Methods:
- Experiments involved challenging laboratory animals with meningococci after administering antimeningococcic serum.
- Serum potency was assessed based on the protection afforded to the animals.
- Results were compared against horse immunization periods, clinical efficacy in human meningitis cases, and agglutination titers.
Main Results:
- The protective power observed in animal experiments was highly variable.
- Results did not correlate with the quality of sera based on horse immunization duration.
- Animal protection tests showed no relation to clinical efficacy in human meningitis cases or agglutination titers.
Conclusions:
- Protective power in laboratory animals is an unsuitable index for antimeningococcic serum's value in human medicine.
- The agglutination titer is a superior standard for determining antimeningococcic serum potency compared to animal protection tests.
